Ofatumumab
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1036 publications
Ofatumumab Interruption Results in Disease Reactivation: A Case Report.
Journal: International journal of MS care
Published: October 24, 2026
Cost-effectiveness of cladribine tablets for the treatment of active relapsing-remitting multiple sclerosis in the United Kingdom.
Journal: Current medical research and opinion
Published: October 22, 2026
Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: October 09, 2026
Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study.
Journal: Neurology
Published: October 05, 2026
Ofatumumab and Ocrelizumab: Siblings or Cousins in the Anti-CD20 Family?
Journal: Neurology
Published: October 05, 2026
T-B interactions yield CD3+ B cells and CD20+ T cells with pathogenic features in multiple sclerosis.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 01, 2026
Imaging Features and Prognosis of Anti‑Sez6l2 Encephalitis: A Longitudinal Cohort Study and Literature Review.
Journal: Cerebellum (London, England)
Published: September 01, 2026
Pregnancy Exposure to Anti-CD20 Monoclonal Antibodies in Patients With Multiple Sclerosis: Results From an Italian Multicenter Registry Study.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: August 28, 2026
Monitoring Remyelination and Its Association With Disability Improvement in Multiple Sclerosis Using APART-QSM: A Longitudinal Cohort Study.
Journal: Journal of magnetic resonance imaging : JMRI
Published: August 27, 2026
Multiple sclerosis relapse following gamma knife radiosurgery for meningioma in a patient treated with natalizumab: case report.
Journal: Frontiers in oncology
Published: August 05, 2026
Switching Beyond Rituximab in Primary Glomerular Diseases: A Systematic Review of Within-Patient Efficacy and Safety of Non-Rituximab Anti-CD20 Antibodies.
Journal: Antibodies (Basel, Switzerland)
Published: August 04, 2026
Ocrelizumab versus ofatumumab efficacy and safety after natalizumab discontinuation in multiple sclerosis: a retrospective real-world comparison.
Journal: Journal of neurology
Published: August 03, 2026
Last Updated: 11/08/2026